Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Alkem Labs accused of...

    Alkem Labs accused of fudging trial data by German regulator

    Written by savita thakur thakur Published On 2016-04-16T15:42:52+05:30  |  Updated On 16 April 2016 3:42 PM IST
    Alkem Labs accused of fudging trial data by German regulator

    Mumbai : Alkem Laboratories has been accused by Germany's health regulator of fudging data on clinical trials of an antibiotic and brain disorder drug, becoming the third Indian firm to be scrutinised since 2014 for suspected manipulation of trial data.


    The medicines are now being reviewed by the European Medicines Agency (EMA) on the recommendation of the German regulator, which inspected Alkem's Taloja plant in western India last March.


    Alkem was found to have engaged in "intentional misrepresentation" of data and duplicated results of electrocardiogram (ECG) readings of patients in trials, the German regulator said in a notice sent to the EMA on March 24, 2016.


    The notice and other information on the review dated April 1 was seen by Reuters on the EMA website on Friday.


    In recent years, India's GVK Biosciences and Quest Lifesciences were found to have duplicated ECG data, resulting in the withdrawal of approvals for hundreds of drugs last year.


    The EMA said it was assessing the "benefit-risk" of certain medicines that had received marketing approval based on trials conducted by Alkem between March 2013 and March 2015.


    The drugs include the antibiotic cefuroxime and rulizole, used to treat the neurological disorder amyotrophic lateral sclerosis, sold both by Alkem and Slovenia's Krka, the EMA said. Alkem was conducting trials on the drugs for Krka.


    The German regulator made Alkem aware of its findings on Sept. 8, 2015, according to the notice.


    Mumbai-based Alkem did not immediately reply to requests for comment on Friday. It said last month that UK regulator MHRA had inspected the Taloja plant and made eight observations.


    Krka did not immediately respond to an email seeking comment.


    The German regulator said Alkem's quality management system "neither avoided nor detected" the data manipulation. The regulator has urged the EMA, the medicines regulator for the European Union, to take necessary action and consider if impacted drugs need to be suspended or recalled.


    Alkem, one of the fastest-growing drugmakers in India, debuted on Indian stock exchanges in December, raising more than $200 million in an offering that received an overwhelming response from investors. Since the listing, its shares have dipped 3 percent.


    Apart from conducting clinical trials for drug companies, it sells generic versions of medicines ranging from anti-infectives, anti-diabetics and anti-malaria drugs to 55 countries, including United States and Europe.


    The EMA's opinion will be considered by the European Commission, which will take a final decision on the medicines, the EMA said.

    Alkemanti-diabeticsanti-malaria drugsECGelectrocardiogramEMAEuropean Medicines AgencyGVK Biosciences and Quest Lifesciences
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok